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Abstract
Background: Carotid angioplasty and stenting (CAS) may currently be recommended especially in younger patients with a
high-grade carotid artery stenosis. However, evidence is accumulating that in-stent restenosis (ISR) could be an important
factor endangering the long-term efficacy of CAS. The aim of this study was to investigate the influence of inflammatory
serum markers and procedure-related factors on ISR as diagnosed with duplex sonography.
Methods: We analyzed 210 CAS procedures in 194 patients which were done at a single university hospital between May
2003 and June 2010. Periprocedural C-reactive protein (CRP) and leukocyte count as well as stent design and geometry, and
other periprocedural factors were analyzed with respect to the occurrence of an ISR as diagnosed with serial carotid duplex
ultrasound investigations during clinical long-term follow-up.
Results: Over a median of 33.4 months follow-up (IQR: 14.9–53.7) of 210 procedures (mean age of 67.969.7 years, 71.9%
male, 71.0% symptomatic) an ISR of $70% was detected in 5.7% after a median of 8.6 months (IQR: 3.4–17.3). After multiple
regression analysis, leukocyte count after CAS-intervention (odds ratio (OR): 1.31, 95% confidence interval (CI): 1.02–1.69;
p=0.036), as well as stent length and width were associated with the development of an ISR during follow-up (OR: 1.25,
95% CI: 1.05–1.65, p=0.022 and OR: 0.28, 95% CI: 0.09–0.84, p=0.010).
Conclusions: The majority of ISR during long-term follow-up after CAS occur within the first year. ISR is associated with
periinterventional inflammation markers and influenced by certain stent characteristics such as stent length and width. Our
findings support the assumption that stent geometry leading to vessel injury as well as periprocedural inflammation during
CAS plays a pivotal role in the development of carotid artery ISR.
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Introduction
Cerebral ischemia is one of the most important causes of
mortality in industrialized countries and is associated with
considerable medical and socio-economic problems [1]. Carotid
artery stenosis is known as a leading risk factor for the
development of ischemic stroke and is therefore a major target
of primary and secondary stroke prevention. Randomized
controlled trials and subsequent meta-analyses have demonstrated
that carotid endarterectomy (CEA) in combination with best
medical treatment of cerebrovascular risk factors is currently the
standard treatment for patients with a symptomatic carotid artery
stenosis and some selected patients with an asymptomatic carotid
artery stenosis [2]. During the last decade, carotid angioplasty and
stenting (CAS) has emerged as an alternative treatment modality
and may be used as a complementary treatment to CEA [3–5]. As
has been indicated within the recently published pooled analysis of
the EVA-3S, SPACE, and ICSS studies as well as in the CREST
study, CAS may be a safe treatment option especially in patients
aged ,70 years [6,7]. However, the efficacy of CAS in younger
patients is highly dependent on its long-term outcome. Unfortu-
nately, prospective long-term data are sparse and the current
advantages and complications of CAS are still controversially
debated. Particularly, the long-term patency of carotid artery
stents may be endangered by a pathological neointimal prolifer-
ation and subsequent in-stent restenosis (ISR). ISR is frequently
asymptomatic at diagnosis, but may nevertheless adversely affect
the long-term safety and efficacy of CAS because it could
necessitate a second intervention which might again be associated
with a periprocedural complication.
We know from coronary artery stenting that inflammation plays
a pivotal role in the pathogenesis of ISR, causing neointimal
proliferation through the stent meshes [8–10]. In this scenario,
technical factors such as stent dimensions or pre- and postdilation
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This could cause inflammation and thus contribute to the
development of an ISR after CAS due to neointimal proliferation.
In vivo, an inflammatory process can easily be monitored with
inflammatory serum biomarker for instance C-reactive protein
(CRP), which has shown its predictive value in the clinical and
imaging outcome of patients undergoing coronary and carotid
artery stenting [11–13].
The aim of the current study was to investigate the influence of
periprocedural serum inflammatory biomarkers and procedural
technical characteristics on the incidence of ISR in patients
undergoing CAS during long-term follow-up.
Methods
Ethics statements
The current study is in accordance with the Declaration of
Helsinki and ICH/GCP guidelines. The analysis was approved by
the Ethics Committee of the University of Go ¨ttingen, Germany.
Study design
197 patients (215 arteries) with a symptomatic carotid artery
stenosis $70% or an asymptomatic carotid artery stenosis $90%
(degree of stenosis was measured according to the European
guidelines (ECST) [14]) who underwent carotid artery stenting
between May 2003 and June 2010 and were prospectively
examined at our institution were consecutively included in our
study. Exclusion criteria for this current analysis were unstable
neurological conditions, progressive stroke, stenosis caused by
dissection or markedly elevated CRP levels or leukocyte counts
preinterventionally due to manifest infections such as pneumonia
or urinary tract infections.
Patients who had experienced a transient or permanent
ipsilateral ocular or cerebral ischemic event within the past six
months due to carotid artery stenosis were considered symptom-
atic. The degree of stenosis was determined by carotid duplex
ultrasound imaging according to the ECST guidelines and
angiographically confirmed during the stenting procedure. All
patients received detailed information about the three different
treatment strategies (CEA, CAS, and best medical treatment) and
their specific advantages and potential complications. With respect
to the CAS procedure, all patients were informed about the
investigational nature of CAS and gave their written informed
consent.
Clinical data collection
An experienced stroke neurologist (K.W., S.S. or K.G.)
performed a complete neurological examination before the
procedure, immediately after CAS and at every visit during
long-term follow-up, and documented all clinical data. The
following cerebrovascular risk factors were recorded using history
or direct measurements: hypertension (blood pressure $140/
90 mmHg measured on repeated occasions or presence of
antihypertensive drugs), hyperlipidemia (fasting serum cholesterol
levels $200 mg/dl or statin therapy), smoking (current or within
the previous year), diabetes mellitus (HbA1c $6.5%, fasting blood
glucose $120 mg/dl, or presence of antidiabetic drugs), coronary
artery disease (history of angina, myocardial infarction, percuta-
neous transluminal angioplasty or surgery), peripheral occlusive
arterial disease (history of typical clinical presentation, percutane-
ous transluminal angioplasty or surgery) and the presence of
contralateral carotid artery stenosis or occlusion (as assessed with
ultrasound).
Imaging methods
Carotid duplex ultrasound imaging using a combination of
direct and indirect criteria as well as the presence and extent of
intrastenotic and poststenotic flow yielded the degree of stenosis
before CAS and the diagnosis of an ISR. In detail, as direct criteria
for the local degree of stenosis, the peak systolic flow velocities
(PSV) within and distal of the carotid artery stenosis, the peak
enddiastolic flow velocity in the stenosis, the internal carotid
artery-to-common carotid artery PSV ratio, and the prestenotic
and poststenotic frequency patterns were documented. Whenever
possible, the residual vessel lumen in the B image and the colour-
coded residual vessel area were determined. As indirect criteria, a
reversal flow of the supratrochlear artery and the anterior cerebral
artery as an indicator of an inadequate intracerebral crossflow and
the pulsatility of the ipsilateral common carotid artery were taken
into account. As there are no common criteria available for
defining an ISR and current literature suppose different criteria
[15–17], we used locally adopted criteria with a PSV $300 cm/s
as a key feature representing an ISR of $70% (Figure 1).
All examinations were performed in a standardized form in the
same vascular laboratory with the same ultrasound equipment (Acuson
Sequoia
TM 512, Siemens, San Jose ´, CA) under the supervision of an
experienced, board certified vascular neurologist (K.G.).
Contrast-enhanced reference imaging (computer tomography
angiography and/or conventional angiography) was done at the
discretion of the treating physician, in most of the cases if the
collateral flow pattern changed, in case of the occurrence of
clinical stroke-symptoms attributable to the treated vessel or if a re-
intervention was anticipated.
Laboratory data collection
Peripheral blood samples for routine measurement of CRP and
leukocyte count were taken 24 hours before and after CAS.
Furthermore, a serum lipidprofilecontaining high density lipoprotein
(HDL), low density lipoprotein (LDL) and total cholesterol as well as
triglycerides were tested during hospitalization after overnight fasting.
All parameters were determined by standard laboratory methods
at the Department of Clinical Chemistry of the University Medical
Center of the Georg-August-University Go ¨ttingen, Germany. In
detail, C-reactive protein was assayed by an automated immuno-
precipitation technique with photometric analysis. The reference
range of our local laboratory is #8.0 mg/l, the lower detection limit
0.2 mg/dl. The leukocyte count was also measured sample
dependent by automated techniques with one of the following
haematology analyzers: Beckman Coulter AcT 5 diff AL (Beck-
mann Coulter, Brea, CA, USA), ADVIAH 120 (Bayer Diagnostics,
Mu ¨nchen, Germany) or Abbot Cell-Dyn Sapphire (Diamond
Diagnostics, Holliston, MA, USA) with a local reference range of
4000–11000/ml. A following manual count was carried out if
pathological results occurred.
Serum triglycerides, total cholesterol and HDL cholesterol were
measured in fasted blood samples using an autoanalyzer. LDL
cholesterol was calculated using the Friedwald’s formula [18].
CAS procedure
In the majority of cases, the intervention was done under
anaesthesiology stand-by via a femoral approach by an experi-
enced interventional neuroradiologist. Stent-type and the use of
filter-based protection devices were chosen at the discretion of the
interventionalist. All patients received orally administered aspirin
(100 mg/d) and clopidogrel (75 mg/d) at least 3 days before the
procedure. Aspirin was administered indefinitely and clopidogrel
was withdrawn 6 weeks after CAS. All patients were routinely
monitored in our intensive care or stroke unit overnight and were
Predictors for In-Stent Restenosis
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neurological status of the patient and a duplex sonography was
performed before discharge.
Follow-up protocol
A neurologist experienced in neurovascular diseases examined
each patient and recorded clinical complications at the hospital’s
outpatient clinic at 3, 6, and 12 months after the CAS-procedure
and every 6 months thereafter. During these postinterventional
visits serial duplex sonography was routinely performed according
to a standardized protocol.
Statistical analysis
Continuous values were expressed as mean 6 SD and
nominal variables as count and percentages. Median values with
the corresponding interquartile range (IQR) were computed for
non-normally distributed variables. A two-sided T-test was used
for comparison of normally distributed variables and the non-
parametric Kruskal Wallis testf o rn o tn o r m a l l yd i s t r i b u t e d
values. For comparisons of categorical data we used two-tailed
Chi-square statistics with Yates’ correction or the Fisher’s exact
test when the predicted contingency table cell values were less
than five. A two-sided p value of less than 0.05 was considered
to indicate a statistically significant difference. Multiple
binominal regression analysis was conducted for those variables
with a p,0.1 on univariate level to estimate a potential effect on
the development of an ISR (p to enter=0.05, p to leave=0.1)
using additive and multiple interaction terms. All statistical
analyses were performed using SPSS (Version 17, SPSS Inc.,
Chicago, Ill).
Figure 1. In-stent restenosis after carotid artery stenting as diagnosed during routine duplex sonography follow-up. Duplex
sonography (B-mode) of a carotid artery after stenting showing a narrowing in the middle part of the stent due to a calcified plaque (A). During the
routine follow-up investigation after six months there was a typical aliasing phenomenon indicating focal flow acceleration (B). Peak systolic velocity
reached up to 520 cm/s (C) with a markedly disturbed poststenotic frequency pattern (D). The reconstructed contrast enhanced computer
tomography confirmed the high-grade in-stent restenosis (E).
doi:10.1371/journal.pone.0022683.g001
Predictors for In-Stent Restenosis
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Patient characteristics and follow-up
We retrospectively screened 215 patients (237 arteries) consec-
utively undergoing elective carotid artery stenting between May
2003 and June 2010 from our prospectively achieved database.
The data of 21 patients (22 arteries) had to be excluded due to
missing follow-up data, additionally 5 patients (5 arteries) with
clinical signs of pulmonary or urinary tract infections and/or
markedly elevated CRP levels or leukocyte counts were excluded.
Complete clinical follow-up data were available for the remaining
210 CAS procedures (mean age of 67.969.7 years, 71.9% male),
with a median duration of follow-up of 33.4 months (IQR: 14.9–
53.7 months). A PSV $300 cm/s corresponding to an ISR $70%
was detected in 12/210 (5.7%) arteries after a median of 8.6
months (IQR: 3.4–17.3). In 9 of the 12 ISR a new crossfilling via
the anterior communicating artery or supraorbital artery could be
identified as additional supporting sonographic criteria for a high
grade restenosis. A contrast-enhanced reference imaging con-
firmed the ISR (see Figure 1) in nine cases (seven by conventional
angiography, two by CT angiography), failed in one case (CT
angiography) and was not done in two cases. The detailed clinical
baseline patient characteristics are given in table 1.
Periinterventional inflammatory serum biomarkers
Preinterventional CRP (CRPpre) values were not normally
distributed and had a median value of 2.1 mg/dl (IQR: 0.0–
6.8 mg/dl). According to our local laboratory reference values
pathological CRPpre values of .8.0 mg/dl occurred in 37 patients
(21.1%). There was a statistically significantly higher median CRP
value of 10.4 (IQR: 1.5–23.7 mg/dl) in the group of patients with
an ISR in comparison to the group of patients without an ISR
(2.0 mg/dl, IQR: 0.0–6.6 mg/dl) during follow up (p=0.022, see
table 2). Postinterventional CRP (CRPpost) did not differ between
the groups (p=0.314) on univariate level.
Preinterventional leukocyte counts (Leukopre) were normally
distributed and reached 7626/ml( 62040/ml) in the group without
and 8300/ml( 63013/ml) with ISR (p=0.283).
The postinterventional leukocyte count (Leukopost) showed a
significant increase in patients with the occurrence of an ISR
during follow-up in the univariate analysis (8526/ml vs. 10433/ml;
p=0.035).
The lipid profile did not differ significantly between both
groups.
CAS-related interventional parameters
In most of the cases (79%) a closed-cell design Carotid
WALLSTENT (Boston Scientific, Natick, Massachusetts) was
used. The stent cell design did not differ between the groups with
and without ISR during follow-up (see Table 2, p=0.695). There
was yet a significantly narrower stent width in the group with the
occurrence of an ISR (mean: p=0.019), as well as a trend towards
ISR formation during follow-up in those patients with a longer
stent length (p=0.068). There was no significant association
between the use of multiple stents, pre- and postdilation and ISR
on the univariate level (Table 2).
Multivariate analysis
After applying binominal multivariate analysis with variables
which were imbalanced on univariate analysis (CRPpre, Leukopost,
stent length and width) and correcting for possible influencing
variables such as age, gender and symptomatic status of the carotid
artery (symptomatic vs. asymptomatic), the variables Leukopost,
stent length and stent width remained significant for predicting the
occurrence of an ISR (Odds ratio (OR) and 95% confidence
interval (CI): OR 1.31, 95% CI 1.02–1.69, p=0.036; OR 1.25,
95% CI 1.05–1.65, p=0.022 and OR 0.28, 95% CI 0.09–0.84,
p=0.01, respectively, see table 3).
Discussion
The aim of our study was to analyze the effect of periinterven-
tional serum inflammation markers and procedure related
technical factors during CAS on the development of an in-stent
restenosis during long-term follow-up. Our results suggest that
post-procedurally elevated leukocyte count as an inflammatory
serum marker is an independent predictor for subsequent ISR.
Moreover, the occurrence of ISR is markedly regulated by stent
dimensions, i.e. the thinner and longer the deployed stent the more
frequently a restenosis could be detected.
The pivotal role of vascular inflammation in the development of
ISR has been well documented in the context of coronary artery
stenting [11]. ISR is mostly triggered by an endothelial disruption
and abrasion which is caused by balloon inflation and stent
placement. This vascular injury initiates the release of several
mediators leading to adhesion of thrombocytes, neutrophiles and
monocytes. These cells, for their part, release vasoactive,
thrombogenic, lymphocytic, and mitogen substances, which lead
to vasoconstriction, vascular remodelling, neointimal proliferation,
thrombosis and inflammation finally resulting in ISR [8,19].
Assuming a similar pathophysiology of ISR within the carotid
arteries, the periinterventional monitoring of such inflammatory
markers may be useful for the prediction of ISR. The rate of ISR
$70% within our study population was 5.7% and occurred early
after a median duration of 8.6 months follow-up, suggesting more
an intimal hyperplasia than an atherosclerotic burden as the main
cause of stenosis.
To identify patients with a higher risk for ISR is of high
relevance for clinical routine practice because a tight follow-up in
these patients is warranted. The inflammatory biomarker CRP has
proven its predictive value of clinical outcome and ISR in patients
undergoing coronary and carotid artery stenting [11,13,20].
Within our patient cohort, the predictive value of preintervention-
ally elevated CRP could only be shown on a univariate level
Table 1. Baseline patient characteristics (n=210).
Variable Data
Mean age (years 6 SD) 67.9 (69.7)
Male sex 151 (71.9%)
Right sided carotid stenosis 89 (44.3%)
Symptomatic carotid stenosis 149 (71.0%)
Arterial hypertension 191 (91.0%)
Hyperlipidemia 140 (66.7%)
Tobacco use 63 (30.0%)
Diabetes mellitus 62 (29.5%)
Coronary artery disease 61 (29.0%)
Peripheral occlusive arterial disease 41 (19.5%)
Contralateral carotid occlusion 28 (13.3%)
Median follow-up time (months, IQR) 33.4 (14.9–53.7)
Restenosis $70% during follow-up 12 (5.7%)
doi:10.1371/journal.pone.0022683.t001
Predictors for In-Stent Restenosis
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22683whereas it did not remain significant after applying multivariate
regression analysis due to interaction effects. Moreover, our data
could not support an association between CRPpost and the
formation of ISR as has been demonstrated previously [21]. This
may be attributable to the plasmakinetics of CRP showing a
delayed increase after the triggering event [22]. In fact, the most
predictive increase of postprocedural CRP for ISR could be
detected 48 hours after CAS [21] and this might have been missed
since our CRP samples were drawn within 24 hours of the CAS
procedure.
In contrast to CRP the leukocyte count is known as an
inflammation marker rising immediately and rapidly after injury
[23]. This might explain why our results showed a significant
association between postprocedural leukocyte count and ISR, but
failed to demonstrate a relation between postprocedural CRP and
ISR.
Technical and procedural factors during CAS could also play
an important role in the development of ISR because injury to the
intima of the stented artery may cause a hyperplasia. Usually, the
selection of the stent length and width are based on angiographic
findings in order to appropriately cover the stenosis. Our data
show a significant correlation between stent width and ISR. The
wider the stent was the less likely was the occurrence of ISR during
follow-up. It is conceivable that a stent with a larger diameter
results in a reduced flow-velocity, less turbulences and thus in less
frequent ISR. Our data are supported by similar results of Clark et
al., demonstrating that an underexpanded stent with a small final
lumen had a correspondingly higher risk for ISR during serial
intravascular ultrasound follow-up [24].
Moreover, a greater length of the deployed stent yielded a more
frequent occurrence of ISR within our patient cohort and might
be explained by a consecutive longer lesion length which has
repeatedly been identified as an independent predictor for
periprocedural complications [25,26]. Apart from certain ana-
tomical considerations concerning e.g. the distance between
stenosis and carotid bulb or the presence of poststenotic kinking,
the interventionalist’s choice of stent length is mainly based on the
length of the stenotic lesion and may represent an overall marker
for the carotid plaque burden. Our data support the theory that
the risk of vessel injury with subsequent inflammation and possible
ISR development seems to be higher in larger and longer carotid
plaques because longer stents may have been used and resulted in
an extended intimal damage.
Currently, the clinical impact of an ISR is still controversially
discussed. The development of an ISR was associated with poor
sequelae in a single-center study [27] whereas the SPACE-trial did
not find a higher stroke incidence during follow-up in patients with
an ISR [28], assuming a benign course of this entity. Even if
sufficient long-term data assessing the clinical impact of a re-
stenosis after CAS will be available in the future, it is still to be
expected that a higher degree of re-interventions even in clinically
silent ISR will be performed in these patients which again might
be accompanied by a periinterventional risk.
Table 2. Periprocedural variables.
Variable No Restenosis In-Stent Restenosis p value
n=198 n=12
Serum parameters
Leucocytepre count/ml (mean, SD) 7626 (62040) 8300 (63013) 0.283
CRPpre mg/dl (median, IQR) 2 (0–6.6) 10.4 (1.45–23.7) 0.022*
Leucocytepost count/ml (mean, SD) 8526 (62525) 10433 (64177) 0.035*{
CRPpost mg/dl (median, IQR) 10.1 (4.5–24.9) 9 (3.0–11.2) 0.314
Cholesterol mg/dl (mean, SD) 195 (649) 192 (658) 0.885
Triglycerides mg/dl (mean, SD) 148 (672) 123 (661 0.439
LDL mg/dl (mean, SD) 133 (640) 123 (650) 0.587
HDL mg/dl (mean, SD) 47.8 (613) 44.8 (613) 0.620
Interventional parameters
Predilatation 21 (10.9%) 3 (25.0%) 0.153
Postdilatation 189 (95.5%) 10 (83.3%) 0.125
Multiple stents used 10 (5.1%) 1 (8.3%) 0.485
Stent length (mean, SD) 37.6 (65.5) 40.7 (67.0) 0.068*{
Stent width (mean, SD) 7.4 (61.0) 6.9 (61.1) 0.019*{
Closed cell stent design 165 (83.3%) 11 (91.7%) 0.695
pre=preprocedural (within 24 hours before CAS), post=postprocedural (within 24 hours after CAS), CRP=C-reactive protein.
*factors included into multiple regression analysis.
{factors remained significant after multiple regression analysis.
doi:10.1371/journal.pone.0022683.t002
Table 3. Statistically significant results of the multiple
regression analysis.
Variable Odds ratio 95% confidence interval p-value
Leucocytepost/1000/ml 1.31 1.02–1.69 0.036
Stent length [mm] 1.25 1.05–1.65 0.022
Stent width [mm] 0.28 0.09–0.84 0.010
Corrected for: status of the carotid artery stenosis (symptomatic or
asymptomatic), age and gender.
doi:10.1371/journal.pone.0022683.t003
Predictors for In-Stent Restenosis
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of some limitations of our study: Notwithstanding the prospective
data-collection the current analysis was done in a retrospective
manner which could have led to an ascertainment bias. To avoid a
statistical bias due to sample size and outcome events the analysis
of variables investigated had been restricted. Finally, CAS
technique improved noticeably during the past few years which
may have biased the results during the recruitment period of the
current analysis.
The current data contribute to the growing knowledge of
factors, which might influence ISR development and are useful for
the future individual patient selection and guidance to achieve an
optimal treatment of a carotid artery stenosis. The fact that
postprocedurally elevated leukocyte count as well as a longer and
thinner stent size are associated with the development of an ISR
after CAS highlight the theory that inflammation initiated by
vessel injury plays an essential role in ISR formation and
encourages a rigorous follow-up of these patients.
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